Mankind Pharma buys women’s health portfolio for ₹797 crore

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹2464.00

prior close

₹2466.80

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.0%-1.1% vs market

Pharmaceuticals peers, median of 152sector-0.7%-0.4% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.4

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.0-1.1-0.7-0.4

Next day

-1.2-0.7-0.5-1.2-0.0

-1.0+0.2-1.2-1.1+0.2

-0.2+0.7-0.9-1.0+0.8

+0.6+0.2+0.5-1.4+2.0

-0.3+0.8-1.1-1.1+0.8

-0.2+0.9-1.1-1.0+0.8

15d

-4.0+1.8-5.8-1.0-3.0

-8.1+2.7-10.8-2.7-5.5

-12.8+1.8-14.6-4.7-8.2

-10.0+0.8-10.8-8.5-1.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma signed a business transfer agreement with wholly owned subsidiary Bharat Serums and Vaccines for its branded generic women’s health medicines portfolio. The deal is valued at ₹797 crore, before closing adjustments. Mankind will pay 50% at closing and the balance within 150 days. Completion remains subject to closing conditions.

Likely market impact

The deal expands Mankind’s branded women’s health portfolio but creates a ₹797 crore payment obligation, with completion still conditional.